论文部分内容阅读
作者对局部不能手术的NSCLC Ⅲ期患者采用每日低剂量卡铂加胸部加速超分割放疗(AHFX),目的是为了确定卡铂的最大耐受剂量(MTD)以及反应率、反应期、第一次复发部位和生存率。 治疗方法:卡铂25mg/m~2或30mg/m~2,星期一至星期五,每天上午放疗前30～60 min静脉给药。如无疾病进展,诱导化-放联合治疗后休息4周,继以4周期的卡铂加强化疗,每次350 mg/m~2,每21天的第1天给药。放疗第1天与化疗同时开始,每次1.5Gy,每天2次,两次之间最少间隔6小时,总
The authors used a daily low-dose carboplatin plus thoracic accelerated hyperfractionated radiotherapy (AHFX) for locally inoperable NSCLC stage III patients in order to determine the maximum tolerated dose (MTD) of carboplatin and its response rate, response period, and first Secondary recurrence sites and survival rates. Treatment: Carboplatin 25mg/m~2 or 30mg/m~2, Monday to Friday, every day 30~60 min before intravenous radiotherapy. In the absence of disease progression, 4 weeks after the induction of combination therapy, 4 weeks of rest, followed by 4 cycles of carboplatin-enhanced chemotherapy, 350 mg/m~2 each time, on the 1st day of every 21 days. The first day of radiotherapy starts at the same time as chemotherapy, 1.5Gy each time, 2 times a day, with a minimum interval of 6 hours between the two.